2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
NextEra Energy filed Dominion Energy's financial statements and unaudited pro forma combined financial information to support its pending merger with Dominion Energy, first disclosed in a May 18, 2026 Form 8-K. The filing estimates total merger consideration at $65,218 million, based on NEE's July 30, 2026 closing price of $87.93, and the figures are preliminary. Completion still requires shareholder approvals and several regulatory approvals, so shareholders of both companies face a deal that is not yet closed.
Each Dominion Energy share converts into $360 million in aggregate cash (pro rata) plus 0.8138 shares of NEE common stock.
Estimated merger consideration is $65,218 million, including about 738 million NEE shares valued at $64,858 million, based on NEE's $87.93 closing price on July 30, 2026.
Preliminary goodwill is $40,053 million, and a 10% change in NEE's stock price would move estimated consideration by about $6,484 million.
Closing requires approvals including Dominion and NEE shareholder votes, HSR Act clearance, and approvals from FERC, the NRC, the Virginia SCC, the North Carolina Utilities Commission and the South Carolina PSC.
EagleRock Land reported second-quarter 2026 revenue of $41.5 million, up from $23.9 million a year earlier, but a net loss of $37.5 million, which includes $57.4 million of IPO share-based compensation. The company now expects 2026 Normalized EBITDA of $129 million to $133 million, above its original internal forecast, and said it bought the Intrepid Ranch for $78.2 million on August 10, 2026.
Reported Q2 2026 revenue of $41.5 million versus $23.9 million in Q2 2025; normalized revenue of $46.8 million rose 32.3% from Q1 2026
Net loss of $37.5 million for the quarter, including $57.4 million of IPO share-based compensation expense
2026 Normalized EBITDA guidance of $129 million to $133 million, above the original internal forecast
Acquired Intrepid Ranch, about 50,000 acres in Lea County, New Mexico, from Hydrosource Logistics for $78.2 million
JBS reported second-quarter 2026 net sales of $23.9 billion, up 14% from a year earlier, but posted a net loss attributable to the company of $102 million, or -$0.10 per share, compared with net income of $528 million, or $0.48 per share, in the prior-year quarter. The company also said Wesley Batista Filho, 34, will become Global CEO in January 2027, succeeding Gilberto Tomazoni, which matters to shareholders because it sets a new leadership structure.
Net sales of $23.9 billion for the quarter ended June 30, 2026, versus $21.0 billion a year earlier.
Net loss attributable to JBS of $102 million (-$0.10 per share), versus net income of $528 million ($0.48 per share); adjusted EPS was $0.20 versus $0.52.
IFRS Adjusted EBITDA of $1,429 million, down 18%; net leverage was 3.1x.
Wesley Batista Filho to become Global CEO effective January 2027; Gilberto Tomazoni steps down as Global CEO and will become Vice Chairman and Senior Advisor.
On August 4, 2026, Olenox Industries amended its May 29, 2025 Stock Purchase Agreement and Registration Rights Agreement with General Alpha Ltd. The amendment lets the purchaser deduct up to 30% of a Put amount to pay outstanding principal or interest on notes it holds, removes the True-Up and Review of Public Disclosures sections, narrows anti-dilution protection, and extends the purchase agreement's expiration to August 3, 2028. The changes alter terms governing the company's equity financing with this investor, which bears on shareholder dilution and protections.
Amendment dated August 4, 2026 changes the May 29, 2025 Stock Purchase Agreement and Registration Rights Agreement with General Alpha Ltd.
Purchase Agreement expiration date moved from May 8, 2026 to August 3, 2028.
Purchaser may deduct up to 30% of the Put amount to pay principal or interest on notes or convertible notes owed to it.
Sections 7.5 True-Up and 6.10 Review of Public Disclosures removed; anti-dilution now excludes certain share issuances, including those to insiders and conversions of preferred stock.
An entity controlled by Stellex Capital Management agreed to buy all 1,604,326 common shares held by Corre Partners Management and its affiliates at $35.50 per share in a privately negotiated sale. Team, Inc. issues no shares and receives no proceeds, and Stellex is expected to own about 35% of the outstanding common stock upon closing, along with preferred stock and warrants it received in September 2025. Separately, Corre irrevocably waived its board observation and nomination rights, including the right to designate the Chairman, effective August 6, 2026.
Stellex-controlled entity to acquire 1,604,326 common shares from Corre at $35.50 per share.
Team, Inc. will not issue shares or receive proceeds from the transaction.
Upon closing, Stellex is expected to own about 35% of common stock, plus preferred stock and warrants issued in September 2025.
Corre waived its board observation and nomination rights, including the right to designate the Chairman, effective August 6, 2026; rights tied to the Lender Director remain in place.
Team, Inc. reported unaudited second-quarter 2026 revenue of $228.7 million, down 7.8% from $248.0 million a year earlier, and a net loss of $6.8 million versus $4.3 million. The company blamed deferred turnaround and maintenance work at oil, gas and petrochemical customers, and said it expects results toward the bottom half of its full-year 2026 guidance ranges, which it maintained.
Q2 2026 revenue $228.7 million vs. $248.0 million in Q2 2025; Adjusted EBITDA $12.8 million vs. $24.5 million
Net loss attributable to common shareholders $9.8 million, or $2.15 per share, vs. $0.95 per share loss a year earlier
Full-year 2026 guidance maintained: revenue $920 million to $945 million and Adjusted EBITDA $68 million to $73 million, with results expected toward the bottom half of those ranges
Total debt $326.3 million at June 30, 2026, up from $297.2 million at fiscal year-end 2025
Sable Offshore reported second-quarter 2026 revenue of $137.1 million and $9.4 million of positive operating cash flow, its first full quarter of revenue and positive operating cash flow since inception. The company also cut its second-half 2026 capital spending midpoint by 41% to $85 million, but it absorbed $18.5 million of demurrage charges and refinanced its debt on higher-cost terms, including a 15.0% term loan and $115.0 million of new common stock sold at $3.08 per share.
Q2 2026 total revenue of $137.1 million and operating cash flow of $9.4 million, the first full quarter of each since inception.
$18.5 million of non-recurring demurrage charges recognized in operating expenses in the second quarter.
July 2, 2026 refinancing: $675.0 million Term Loan B at a 15.0% coupon due December 15, 2028; $345.0 million 6.5% convertible notes due July 1, 2031; $115.0 million of common stock at $3.08 per share.
Second-half 2026 midpoint capex reduced 41% to $85 million; oil sales constrained to a maximum of 40,000 gross barrels per day from July, with relief expected from the back half of August.
On August 10, 2026, MPT's operating partnership closed a private placement and private exchange issuing $2.4 billion of 9.25% senior secured notes due February 15, 2032. The company said proceeds will fund the full redemption of its 2026 senior notes and a partial redemption of its 2027 senior notes, and the exchange refinanced about $1.5 billion of unsecured notes maturing from 2027 to 2031.
$2.4 billion aggregate principal of 9.25% senior secured notes due February 15, 2032, issued August 10, 2026
Proceeds to fully redeem 2026 senior notes and partly redeem 2027 senior notes; private exchange refinanced about $1.5 billion of 2027–2031 unsecured notes
Interest paid semi-annually on June 15 and December 15, starting December 15, 2026; holders may require repurchase at 101% upon a change of control
Shareholders approved an amendment on August 4, 2026 that extends the deadline for Collective Acquisition Corp. to complete an initial business combination from August 8, 2026 to August 8, 2027. Holders of 12,863,312 Class A ordinary shares elected to redeem, and an estimated $135.2 million (about $10.51 per share) will be paid from the trust account, leaving an estimated $15.9 million in the trust.
Articles Amendment approved by special resolution at the August 4, 2026 extraordinary general meeting: 15,841,860 for and 1,719,170 against
Adjournment Proposal approved by ordinary resolution: 16,779,914 for and 781,116 against
12,863,312 Class A ordinary shares redeemed for a pro rata share of the trust account
Estimated $135.2 million to be removed from the trust account; estimated $15.9 million to remain
Jazz subsidiary Jazz Pharmaceuticals, Inc. agreed on August 10, 2026 to acquire Actio Biosciences, Inc. through a merger, with Actio becoming a wholly owned subsidiary. The upfront value starts at an initial $820 million, adjusted for items such as cash, debt and unpaid expenses, and holders may also receive up to $500 million in milestone payments tied to ABS-1230. Completion depends on conditions including HSR antitrust clearance, approval by holders of at least 85% of Actio's shares, and a spin-out of non-ABS-1230 programs.
Initial aggregate upfront value of $820 million, subject to cash, debt, unpaid expense and tax adjustments
Up to $500 million in milestones: $250 million on regulatory approval for KCNT1-Related Epilepsy, $100 million at $500 million annual net sales, and $150 million at $1 billion annual net sales
Closing requires completion of a spin-out of non-ABS-1230 programs into a new company in which Parent takes a minority stake
If the merger has not closed by an End Date five months after signing, either party may terminate; the agreement contains no termination fees
Mistras Group reported second-quarter 2026 revenue of $193.1 million, up 4.2%, and GAAP net income of $7.6 million, or $0.23 per diluted share, compared with $3.0 million, or $0.10, a year earlier. The company raised its full-year 2026 guidance to $740.0 million to $755.0 million in revenue and $92.0 million to $95.0 million in Adjusted EBITDA, and said net debt was $150.1 million at June 30, 2026.
Q2 revenue of $193.1 million, up 4.2%, with gross profit margin of 29.2%
GAAP diluted EPS of $0.23 vs. $0.10 a year earlier; income from operations of $12.9 million vs. $8.4 million
2026 guidance raised to $740.0 million to $755.0 million in revenue and $92.0 million to $95.0 million in Adjusted EBITDA
Net debt of $150.1 million at June 30, 2026; trailing leverage ratio of 2.2x
Helios Technologies reported second-quarter 2026 net sales of $231.9 million, up 9% from the prior year, and diluted EPS of $0.66 versus $0.34. The company raised its full-year 2026 sales and adjusted diluted EPS outlook, which matters to shareholders because it signals higher expected earnings for the year.
Q2 2026 net sales were $231.9 million, up from $212.5 million; gross margin was 34.6%, up 280 basis points
Diluted EPS was $0.66 versus $0.34; non-GAAP adjusted diluted EPS was $0.88 versus $0.59
FY2026 sales outlook raised to $880 to $900 million from $840 to $870 million; adjusted diluted EPS outlook raised to $3.05 to $3.25 from $2.75 to $3.00
Net-debt-to-adjusted-EBITDA leverage fell to 1.4x from 2.6x a year earlier; the company paid its 118th consecutive cash dividend
Purple Innovation reported second-quarter 2026 net revenue of $98.3 million, down 6.5% from a year earlier, driven by lower wholesale revenue, while its GAAP net loss narrowed to $3.2 million. The company lowered its 2026 revenue guidance to $420 million to $440 million, so shareholders face weaker top-line expectations even as profitability measures improved.
Q2 2026 net revenue was $98.3 million, down 6.5% from $105.1 million; wholesale revenue fell 19.1% to $37.4 million while showroom revenue rose 16.6%
GAAP net loss was $3.2 million, a $14.1 million improvement; adjusted EBITDA was $2.1 million versus a $2.4 million loss a year earlier
2026 revenue guidance lowered to $420 million to $440 million; adjusted EBITDA guidance is $20 million to $25 million
Company regained compliance with the Nasdaq minimum bid price requirement after the quarter ended
Commercial Vehicle Group promoted Angie O'Leary, who has served as interim Chief Financial Officer since March 2026, to permanent EVP and Chief Financial Officer effective August 6, 2026. The filing gives her a $425,000 base salary, a 65% target bonus and a long-term incentive opportunity of at least 120% of base salary beginning in 2027, which shows the board's decision to make the role permanent.
Angie O'Leary, age 45, promoted to EVP and Chief Financial Officer, effective August 6, 2026
Served as interim CFO since March 2026 and previously as Senior Vice President, Corporate Controller and Chief Accounting Officer since December 2020
Base salary $425,000; target bonus 65% of base salary; long-term incentive of no less than 120% of base salary beginning in 2027; change-in-control severance equal to 12 months
Press release dated August 10, 2026 announced the appointment; CEO James Ray said the company is pleased to appoint her as permanent CFO
Trump Media & Technology Group reported a second-quarter 2026 net loss of $238.1 million and an Adjusted EBITDA loss of $223.5 million, compared with a net loss of $20.0 million a year earlier. Revenue rose 89% to $1.7 million, and the company said most of the loss was non-cash, including $190.4 million of unrealized losses on digital assets and equity securities. The results matter to shareholders because the loss widened sharply even as the company launched its first data licensing product and said it is working toward a merger with TAE Technologies.
Net loss of $238.1 million for the quarter ended June 30, 2026, versus $20.0 million in the same quarter of 2025
Revenue of $1.7 million, up 89% from $0.9 million in the second quarter of 2025
Non-cash losses included $190.4 million of unrealized losses on digital assets, digital assets pledged, and equity securities
Truth API data licensing product launched August 1, 2026; the company expects the TAE merger to close in the fourth quarter of 2026
HWH International Inc. closed a $10,000,000 private sale of 20,000,000 common shares and warrants for 160,000,000 more shares to Smart Dynamics Technology Limited on August 10, 2026, leaving the buyer with about 67.3% of outstanding stock. The filing names HWH International Inc., not EnerSyn Global Inc. (ESYN) as stated in the request, so the ticker and company name should be verified before publication. Shareholders face substantial dilution, the loss of the prior controlling holder's dominance, and anti-dilution limits on new equity sales for two years.
20,000,000 shares sold plus warrants for 160,000,000 shares at $0.63 per share, expiring August 10, 2030, for $10,000,000 total
Purchaser holds about 67.3% of outstanding shares; Chairman and CEO Heng Fai Chan's stake falls to 27% from 82.4% before closing
Board expands from five to eight seats, with Liu Chang, Liu Ming Xing and Liu Ming Hui appointed August 10, 2026
Company issued 2,000,000 stock awards on August 7, 2026, including 1,480,000 shares to Heng Fai Chan
Amentum reported third-quarter fiscal 2026 revenue of $3,490 million, down 2% from $3,561 million a year earlier, while GAAP net income rose to $66 million from $10 million and adjusted diluted EPS rose to $0.67 from $0.56. The company raised its fiscal 2026 guidance for Adjusted EBITDA and adjusted diluted EPS but cut its revenue guidance, so shareholders see mixed signals on the year.
Revenue of $3,490 million fell 2% year over year; diluted EPS was $0.27 versus $0.04 and Adjusted EBITDA was $290 million, up 6%.
Free cash flow was $135 million, up 35% from $100 million; backlog reached $48.2 billion, up 8%.
FY2026 revenue guidance was cut to $13,800-$13,950 million from $13,950-$14,300 million.
FY2026 Adjusted EBITDA guidance was raised to $1,115-$1,140 million and adjusted diluted EPS guidance to $2.40-$2.50 from $2.25-$2.45.
AECOM reported fiscal third-quarter 2026 results for the quarter ended June 30, 2026, with GAAP revenue of $3.6 billion, down 14% from a year earlier, and a $76 million operating loss. The results include a $337 million pre-tax charge on a Construction Management project, and the company lowered its fiscal 2026 guidance to reflect the charge and slower net service revenue growth. For shareholders, the charge drives the loss and reduces the expected full-year free cash flow to about $300 million, while backlog rose to a record $27.8 billion.
Q3 GAAP revenue was $3.6 billion, down 14%; operating loss was $76 million and diluted loss per share was $0.65.
A $337 million pre-tax charge on a Construction Management project was recorded; excluding it, adjusted EBITDA was $329 million and adjusted EPS was $1.49.
Fiscal 2026 adjusted EPS guidance is $3.95 to $4.15 including the charge, and free cash flow is projected at approximately $300 million.
Total backlog rose 13% to a record $27.8 billion; the project is expected to reach substantial completion in the second quarter of fiscal 2027, and recovery claims may take several years.
WEBTOON Entertainment reported second-quarter 2026 revenue of $338.5 million, down 2.8% from a year earlier, and a net loss of $14.6 million versus $3.9 million in the prior-year quarter. The company also agreed on August 6, 2026 to buy up to 9,000 shares, about a 60% stake, in South Korean game developer RI Games Holdings in two closings, with the second dependent on a commercial launch milestone.
Q2 revenue $338.5 million, down 2.8% from $348.3 million; up 5.2% on a constant currency basis to $366.4 million
Net loss $14.6 million, or $0.11 per diluted share, versus $3.9 million, or $0.03 per share, a year earlier, driven primarily by increased marketing investment
Adjusted EBITDA $5.5 million versus $9.7 million a year earlier, above the high end of prior guidance
Third-quarter outlook: revenue of $358-$368 million and Adjusted EBITDA of $0.0-$5.0 million; RI Games stake to be consolidated after the second closing
Bakkt reported second-quarter 2026 results with revenue of $170.1 million, down 70.0% from $568.1 million a year earlier, which the company attributed to previously disclosed client transitions and industry-wide softness in digital asset trading volumes. GAAP net income of $80.8 million, or $1.94 per diluted share, was driven by a $98.5 million non-cash gain on the Transchem warrants, while the adjusted EBITDA loss widened to $11.8 million. Shareholders face a sharp revenue decline, and the company reaffirmed its full-year 2026 TTV expectation of approximately $2.5 billion, which depends on client launches ramping in the second half.
Total revenue was $170.1 million in Q2 2026 versus $568.1 million in Q2 2025, a 70.0% decline.
Net income attributable to Bakkt was $80.8 million ($1.94 per diluted share), compared with a net loss of $14.7 million in Q2 2025; the result includes a $98.5 million non-cash gain on Transchem warrants.
Adjusted EBITDA loss was $11.8 million, compared with $9.8 million in Q2 2025.
Cash, cash equivalents and restricted cash were $50.7 million as of June 30, 2026, with no long-term debt; the company continues to expect approximately $2.5 billion of full-year 2026 TTV.
TTEC reported second quarter 2026 revenue of $455.5 million, down 11.3% from a year earlier, with a GAAP net loss of $0.27 per share against $0.14 a year earlier. The company revised its full-year 2026 outlook for its TTEC Engage segment and said its Board authorized management to evaluate strategic alternatives for TTEC Digital, which could affect shareholders.
Q2 2026 GAAP revenue was $455.5 million, down from $513.6 million; non-GAAP EPS was $0.03 versus $0.22 a year earlier.
Full-year 2026 Engage revenue guidance is $1,520 million to $1,550 million; the company said Digital remains in line with its original guidance of $420 million to $440 million.
PJT Partners is advising on the review of TTEC Digital, with no set deadline or timeline.
Net debt was $766.9 million as of June 30, 2026, and the company obtained covenant flexibility under its Credit Facility.
Ceribell reported second-quarter 2026 revenue of $28.1 million, up 33% from $21.2 million a year earlier, and raised its full-year 2026 revenue guidance to $114 million to $117 million. The net loss widened to $19.3 million, or $0.51 per share, from $13.6 million, or $0.38 per share, as operating expenses rose 37%. Shareholders get faster sales growth and a higher outlook alongside a larger loss.
Q2 2026 total revenue $28.1 million, up 33% from $21.2 million in Q2 2025
Net loss $19.3 million, or $0.51 per share, vs. $13.6 million, or $0.38 per share, in Q2 2025
Operating expenses $45.9 million, up 37% from $33.6 million; gross margin 92% vs. 88%, including a one-time benefit from IEEPA tariff refunds
Full-year 2026 revenue guidance raised to $114 million to $117 million; August 2026 credit facility provides up to $60 million of committed capital
Babcock & Wilcox reported second-quarter 2026 revenue of $319.7 million, up 130% from a year earlier, and net income of $14.3 million, compared with a net loss of $58.5 million in the same period of 2025. The company also raised the top of its full-year 2026 Adjusted EBITDA target range to $80.0 million to $105.0 million. Six-month results still show a net loss of $62.7 million, which includes a $64.4 million change in fair value of customer warrants.
Revenue of $319.7 million vs. $138.9 million a year earlier, driven by large project volume including $100.7 million from Base Electron.
Net income of $14.3 million and earnings per share of $0.07, vs. a net loss of $58.5 million and loss per share of $0.63 in Q2 2025.
Adjusted EBITDA of $21.8 million vs. $13.9 million; full-year 2026 Adjusted EBITDA target range raised to $80.0 million to $105.0 million.
Board authorized a share repurchase program of up to $50 million in July; cash, equivalents and restricted cash was $382.8 million at June 30, 2026.
FutureFuel reported second-quarter 2026 net income of $11.4 million, or $0.25 per diluted share, compared with a net loss of $14.2 million a year earlier, on revenue of $78.7 million, up 120.6%. Gross profit included a $9.1 million benefit from selling inventory above hedged prices and $3.2 million of unrealized derivative gains, and the company reiterated its expectation of positive full-year 2026 Adjusted EBITDA excluding derivative timing items. For shareholders, the quarter marked a return to profit, though the first half of 2026 still shows a net loss of $9.2 million.
Q2 2026 revenue of $78.7 million, up from $35.7 million in Q2 2025; Biofuel revenue rose to $52.9 million
Q2 2026 net income of $11.4 million ($0.25 per diluted share) vs. a net loss of $14.2 million in Q2 2025
Adjusted EBITDA of $11.8 million in Q2 2026 vs. a loss of $11.4 million a year earlier; first-half net loss of $9.2 million
Cash and equivalents of $34.4 million at June 30, 2026, up from $22.4 million at March 31, 2026; company expects $22 million in gross proceeds from tax credit monetization in the second half of 2026
Ark Restaurants reported third-quarter 2026 revenue of $40,881,000, down from $43,715,000 a year earlier, with same-store sales down 6.6%. The net loss attributable to the company narrowed to $347,000, or $0.10 per share, from $3,454,000, or $0.96 per share, but the company also disclosed that it must vacate its Bryant Park locations on or about October 16, 2026 unless the court's decisions are reversed or the stay is extended, and those locations accounted for about 14.5% of revenue in the 39 weeks ended June 27, 2026.
Q3 2026 revenue was $40,881,000 versus $43,715,000 for the 13 weeks ended June 28, 2025; same-store sales fell 6.6%.
Net loss attributable to Ark Restaurants was $(347,000), or $(0.10) per share, versus $(3,454,000), or $(0.96) per share, a year earlier.
Bryant Park Grill, Bryant Park Café and The Porch at Bryant Park produced $17.1 million, or about 14.5%, of 39-week revenue; the court-ordered stay of ejectment runs through about October 16, 2026.
The company said it cannot predict the outcome of its appeal, and no impairment was recorded on its New Meadowlands Racetrack investment.
Amplify Energy reported second-quarter 2026 net income of $17.3 million, compared with a net loss of $38.1 million in the first quarter, mainly due to a $22.6 million non-cash unrealized gain on commodity derivatives. The board also approved a share repurchase of up to $15.0 million of common stock, which the company said represents about 10% of outstanding shares at recent prices, while it updated full-year 2026 guidance to reflect larger oil price deductions.
Q2 2026 revenue excluding hedges was $52.7 million, up from $37.5 million in Q1 2026; Adjusted EBITDA was $8.6 million, up from $3.8 million.
Free cash flow was negative $12.9 million in Q2, compared with negative $18.1 million in Q1; Adjusted Net Loss was $1.7 million.
Full-year 2026 lease operating expense guidance was lowered to $80.0 to $95.0 million, from $80.0 to $100.0 million; the oil differential guidance was widened to negative $12.00 to $14.00 per barrel for the year.
The repurchase program runs from August 11, 2026 through December 31, 2026; the company said it may reduce or defer part of its remaining 2026 drilling.
Exodus Movement reported unaudited second-quarter 2026 results, with revenue up 2% to $26.2 million but a net loss of $18.6 million, compared with net income of $37.7 million a year earlier. The results include Monavate and Baanx contributions from May 1, 2026, and general and administrative expenses rose 138% to $44.7 million, so shareholders face higher costs and a loss in place of last year's profit.
Q2 2026 revenue was $26.2 million, up 2% from $25.8 million in Q2 2025.
Net loss was $18.6 million, versus net income of $37.7 million in Q2 2025.
General and administrative expenses rose 138% to $44.7 million from $18.8 million.
Monthly active users fell 6.7% to 1.4 million at the end of Q2 2026 from 1.5 million at the end of Q1 2026.
Playboy reported second-quarter 2026 revenue of $31.2 million, up 11% from a year earlier, and net income of $0.2 million, compared with a net loss of $7.7 million in the second quarter of 2025. The company also announced an agreement to repurchase 16.6 million shares, about 14% of shares outstanding, at $1.05 per share, a 28% discount to market value at the time of the transaction.
Revenue $31.2 million vs. $28.1 million in Q2 2025; direct-to-consumer revenue rose 18.2% to $19.5 million
Net income $0.2 million, or less than a cent per share, vs. net loss of $7.7 million, or $(0.08) per share, a year earlier
Adjusted EBITDA $7.0 million vs. $3.5 million, an increase of 100%; it includes $0.7 million of litigation expenses
Repurchase of 16.6 million shares at a fixed $1.05 per share, supported by a backstop agreement with two significant stockholders
Nu Skin reported second-quarter 2026 revenue of $320.1 million, down 17.1% from $386.1 million, and a GAAP net loss of $249.8 million, or $5.14 per share, driven by a $78.9 million impairment charge and a $167.5 million tax charge for a valuation allowance on deferred tax assets. Excluding these charges, adjusted EPS was $0.20 versus $0.43 a year earlier, and the company set 2026 revenue guidance of $1.28 billion to $1.35 billion and adjusted EPS of $0.70 to $0.90.
Q2 2026 revenue was $320.1 million, down 17.1%, including a $4.0 million foreign exchange impact
GAAP EPS was $(5.14) versus $0.43; EPS excluding impairment and non-cash tax charges was $0.20
Q3 2026 guidance: revenue of $310 million to $340 million and adjusted EPS of $0.10 to $0.20
Full-year 2026 guidance: revenue of $1.28 billion to $1.35 billion, down 14% to 9%, and adjusted EPS of $0.70 to $0.90
Crescent Capital BDC reported a second quarter 2026 net decrease in net assets from operations of $(0.09) per share, compared with a $0.41 gain a year earlier. Net investment income fell to $0.36 per share from $0.42 in the prior quarter, and net asset value per share declined to $17.82 from $18.27 at March 31, 2026. The Board declared a third quarter regular dividend of $0.34 per share, below the $0.42 regular distributions paid per share in each of the two prior quarters shown in the filing.
Total investment income was $36.3 million, down from $37.9 million in the first quarter of 2026 and $43.0 million in the second quarter of 2025.
Net realized losses were $(17.7) million for the quarter, and net investment income was $13.1 million, versus $15.5 million in the prior quarter.
Third quarter 2026 regular dividend declared at $0.34 per share, payable October 15, 2026, to holders of record as of September 30, 2026.
Net debt-to-equity ratio was 1.37x at June 30, 2026, and weighted average cost of debt was 6.13%.
Compass Diversified reported second-quarter 2026 net revenues of $424.0 million, down 11.4% from a year earlier, while net income attributable to Holdings rose to $81.1 million, or $0.86 per share, from a net loss of $51.2 million. The profit improvement was driven largely by a $182.3 million gain on the sale of Sterno's Food Service Business, partly offset by a $58.0 million reduction in the fair value of its receivable from Lugano; the company also kept its 2026 Subsidiary Adjusted EBITDA outlook at $320 million to $365 million and announced that CEO Elias Sabo will retire on December 31, 2026.
Q2 2026 net revenues were $424.0 million, down 11.4% versus Q2 2025; net income attributable to Holdings was $81.1 million, or $0.86 per share.
Q2 results included a $182.3 million gain on the Sterno Food Service Business sale and a $58.0 million reduction in the fair value of the Lugano receivable.
Fiscal 2026 Subsidiary Adjusted EBITDA outlook was maintained at $320 million to $365 million.
Elias Sabo will retire as CEO on December 31, 2026; Zach Sawtelle was appointed Chief Operating Officer and named CEO successor.
At its August 6, 2026 annual meeting, NVE shareholders elected all seven director nominees and approved executive pay and the auditor ratification. Daniel Baker retired as CEO under the previously announced succession plan, and Peter Eames became president and CEO while Baker became board chairman.
Daniel A. Baker retired as president and CEO effective at the shareholders' meeting and was elected chairman of the board.
Peter G. Eames was elected to the board and appointed president and chief executive officer.
Carolyn W. Valentine was elected to the board for the first time and appointed to the Compensation and Nominating/Corporate Governance committees; board size rose from five to seven.
Named executive officer compensation was approved with 3,011,073 votes for and 73,720 against; Boulay PLLP was ratified as auditor with 3,876,455 votes for.
American Public Education reported second-quarter 2026 revenue of $171.7 million, up 5.5%, and net income available to common stockholders of $9.8 million, compared with a loss of $0.3 million a year earlier. The company raised its full-year 2026 revenue, net income and adjusted EBITDA guidance and said it completed the combination of American Public University System, Rasmussen University and Hondros College of Nursing after the quarter ended.
Q2 2026 revenue was $171.7 million, up 5.5% from $162.8 million; diluted EPS was $0.52 versus a loss of $0.02.
Full-year 2026 guidance: revenue $690.0 million to $698.0 million, net income $46.5 million to $52.5 million, adjusted EBITDA $96.0 million to $104.0 million.
Third-quarter 2026 guidance: revenue $164.5 million to $167.0 million and adjusted EBITDA $14.0 million to $17.0 million.
Cash, cash equivalents, restricted cash and short-term investments were $222.8 million at June 30, 2026; $45.0 million remains under the repurchase authorization.
Harrow reported second-quarter 2026 revenue of $70.7 million, up 11% from a year earlier, but posted a net loss of $17.3 million, or $0.46 per share, compared with net income of $5.0 million a year earlier. The company reiterated its full-year 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA, and said the TYRVAYA acquisition is expected to close in the second half of 2026.
Q2 2026 revenue of $70.7 million, up 60% from $44.2 million in Q1 2026 and up 11% from $63.7 million a year earlier.
Adjusted EBITDA loss of $1.2 million in Q2 2026, compared with positive Adjusted EBITDA of $17.0 million in Q2 2025.
Full-year 2026 guidance reiterated: $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA.
Cash and cash equivalents of $83.9 million and loans payable of $292.4 million as of June 30, 2026.
Alico reported third-quarter results for the period ended June 30, 2026, with revenue of $9.0 million, up 7.7% from a year earlier, and net income attributable to common stockholders of $2.1 million, or $0.29 per diluted share, compared with a loss of $18.3 million a year earlier. The company raised its fiscal 2026 guidance, projecting Adjusted EBITDA of about $15 million, cash of about $48 million and net debt of about $37 million.
Q3 revenue was $9.0 million versus $8.4 million a year earlier; nine-month revenue was $16.3 million versus $43.3 million, reflecting the citrus wind-down.
Q3 net income attributable to common stockholders was $2.1 million ($0.29 per diluted share), compared with a loss of $18.3 million ($2.39 per share) in the prior-year quarter.
Fiscal 2026 guidance was raised to Adjusted EBITDA of about $15 million, with year-end cash of about $48 million and net debt of about $37 million.
The company repurchased about 245,000 shares for $10.0 million during the period.
Insight Molecular Diagnostics reported second-quarter 2026 revenue of $239,000, down from $518,000 a year earlier, and a net loss of $11.3 million, or $0.31 per share, versus $9.7 million, or $0.30 per share, in the prior-year quarter. The company also disclosed that the FDA issued an Additional Information Request on its GraftAssureDx submission, which requires a complete response within 180 days; management calls the request routine.
Q2 2026 revenue was $239,000 versus $518,000 in Q2 2025; gross profit was $157,000.
Q2 2026 net loss was $11.3 million ($0.31 per share) versus $9.7 million ($0.30 per share) in Q2 2025; non-GAAP net loss was $8.3 million ($0.23 per share).
The FDA issued an Additional Information Request on GraftAssureDx, with a complete response due within 180 days; the company expects one more FDA meeting before the fourth quarter of 2026.
Cash, cash equivalents and restricted cash was $18.7 million at June 30, 2026; Q2 free cash outflow was approximately $10 million.
GEN Restaurant Group reported second-quarter 2026 revenue of $55.7 million, up 1.2% from a year earlier, while its net loss widened to $4.6 million from $1.7 million and adjusted EBITDA turned negative at $41,000. The company also disclosed a non-binding letter of intent from a nationwide restaurant operator to acquire its U.S. restaurant operations, with the Board reviewing the proposal and no assurance a transaction will result.
Q2 2026 revenue rose 1.2% to $55.7 million, but comparable restaurant sales fell 9.3%.
Loss from operations was $5.2 million, versus $1.9 million in Q2 2025; net loss was $4.6 million, or $(0.14) per share.
Non-binding letter of intent to acquire U.S. restaurant operations; GEN would retain 100% of its CPG and retail business.
Cash of $5.9 million and total debt of $24.0 million as of June 30, 2026, versus $14.6 million at December 31, 2025.
Rapid7 reported second-quarter 2026 total revenue of $210.9 million, down 1.5% from a year earlier, and annualized recurring revenue of $824.0 million, down 2.0%. GAAP net income was $6.1 million, or $0.09 per diluted share, versus $8.3 million, or $0.13, a year earlier. The board also approved a restructuring plan to cut about 12% of the workforce, with $10 million to $11 million in charges expected mostly in the third and fourth quarters of 2026, and the company guided to third-quarter and full-year revenue that is below the prior year.
Q2 2026 total revenue $210.9 million, down 1.5% year over year; GAAP income from operations $3.0 million versus $3.5 million a year earlier
Non-GAAP income from operations $28.9 million, down from $36.3 million; non-GAAP diluted EPS $0.44 versus $0.58
Restructuring plan approved August 7, 2026, reduces workforce by about 12%, with $10 million to $11 million in charges
Third-quarter 2026 revenue guidance $208 million to $210 million (down 5% to 4%); full-year 2026 revenue guidance $837 million to $841 million (down 3% to 2%)
Hims & Hers reported second quarter 2026 revenue of $753.2 million, up 38% from a year earlier, and raised its full-year 2026 revenue guidance to $3.1 billion to $3.3 billion. The company swung to a net loss of $86.3 million from net income of $42.5 million in the prior-year quarter, and Adjusted EBITDA fell to $60.3 million from $82.2 million, so shareholders face higher revenue alongside lower profit.
Q2 2026 revenue was $753.2 million, up 38% year-over-year; subscribers reached 2,891 thousand, up 19%
Net loss was $86.3 million in Q2 2026 versus net income of $42.5 million in Q2 2025; gross margin fell to 64% from 76%
Adjusted EBITDA was $60.3 million versus $82.2 million a year earlier; Free Cash Flow was $(68.2) million
Full-year 2026 revenue guidance raised to $3.1 billion to $3.3 billion; Adjusted EBITDA guidance set at $275 million to $325 million
Rocket Lab reported second-quarter 2026 revenue of $234.1 million, up 62% from a year earlier, and a net loss of $49.3 million, narrowed from $66.4 million. The company guided third-quarter revenue to $250 million to $265 million and said it announced an agreement to acquire Iridium Communications Inc., which the filing does not price.
Q2 2026 total revenue $234.1 million vs. $144.5 million in Q2 2025
Q2 2026 net loss $49.3 million, or $0.08 per share, vs. $66.4 million, or $0.13 per share, a year earlier
Backlog reached $2.36 billion at June 30, 2026, up 137% year over year
Q3 2026 guidance: revenue $250 million to $265 million; GAAP gross margin 29% to 31%
Simon reported second-quarter 2026 results on August 10, 2026, with Real Estate FFO of $1.249 billion, or $3.29 per diluted share, up 7.9% from a year earlier. GAAP net income attributable to common stockholders fell to $483.1 million, or $1.49 per diluted share, from $556.1 million, or $1.70, a year earlier, and the prior-year figure included a $0.21 per share gain. The company raised its full-year 2026 Real Estate FFO per share guidance to $13.20 to $13.30 from $13.10 to $13.25.
Real Estate FFO was $1.249 billion, or $3.29 per diluted share, versus $1.154 billion, or $3.05, in the second quarter of 2025.
GAAP net income attributable to common stockholders was $483.1 million, or $1.49 per diluted share, versus $556.1 million, or $1.70, a year earlier.
Full-year 2026 Real Estate FFO per share guidance was raised to $13.20 to $13.30, from $13.10 to $13.25 previously.
Simon declared a third-quarter 2026 common dividend of $2.25 per share, up $0.10 or 4.7% year over year, payable September 30, 2026.
American Healthcare REIT, through its operating partnership, signed three purchase agreements on August 10, 2026 to acquire eight senior housing communities, called the Kensington Portfolio, for an aggregate price of $873 million. The company expects the first closing, covering the portfolio, in the third quarter of 2026, with the remaining two closings expected by the end of 2026, but it gives no assurance that any closing will occur on that timeline or at all.
Eight senior housing communities with 745 units in California, Maryland, New York and Virginia, for an aggregate price of $873,000,000
Total deposits of $8,730,000 go into escrow within three business days of August 10, 2026 and become non-refundable under specified conditions
Initial closing of the Portfolio Agreement is set for September 1, 2026, with a one-time option to extend to October 15, 2026
Kensington Park and Bethesda closings depend on lender consent on a $56,460,000 existing loan and a stabilization condition, respectively
Skyworks Solutions issued $2.0 billion of senior notes in three tranches due 2028, 2032 and 2036, to help finance about $3.00 billion in cash consideration for its planned acquisition of Qorvo. The 2028 and 2036 notes carry a special mandatory redemption if the Qorvo merger is not completed, which shifts some financing risk back to the company if the deal fails.
Issued $800 million of 5.000% notes due 2028, $600 million of 5.750% notes due 2032 and $600 million of 6.250% notes due 2036
Proceeds, together with existing cash, are intended to fund about $3.00 billion in cash consideration for the Qorvo merger
2028 and 2036 notes must be redeemed early if the Qorvo merger does not close by 11:59 p.m. Pacific Time on November 3, 2027, or if the company abandons or the merger agreement is terminated
Notes were issued under an indenture with U.S. Bank Trust Company, National Association, as trustee
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026, paying in part with 28,942,098 newly issued Class A shares. The company also borrowed a $350 million incremental term loan, with proceeds used as part of the purchase consideration, and says the deal adds a long-term biosimilars growth pillar. The filing does not disclose financial results or the total purchase price, so the effect on earnings and the share count is not yet quantified.
Acquisition of Kashiv BioSciences, LLC closed on August 10, 2026, under a Membership Interest Purchase Agreement dated April 21, 2026
Amneal issued 28,942,098 shares of Class A Common Stock to the sellers in a private placement exempt from registration
$350 million incremental term loan made by Bank of America, N.A. under Amendment No. 4 to the Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as agent
Amneal plans to file Kashiv financial statements and pro forma information by amendment, and to register the shares for resale on Form S-3
Varex Imaging entered into a merger agreement under which Teledyne Technologies will acquire the company, with each Varex share converted into the right to receive $18.90 in cash. The companies put the aggregate transaction value at approximately $1.1 billion, including equity awards and net debt as of April 3, 2026. Closing is expected in early 2027, subject to Varex stockholder approval and regulatory clearances, and the shares would be delisted from Nasdaq if the deal closes.
Cash consideration of $18.90 per share, without interest, subject to tax withholding
Aggregate transaction value of approximately $1.1 billion, per the companies' joint announcement
Expected closing in early 2027, subject to stockholder approval, HSR waiting period expiration and foreign regulatory clearances
Board of Directors of both companies unanimously approved the transaction; no financing condition applies
NIQ reported second-quarter 2026 revenue of $1,124.2 million, up 8.0% from a year earlier, and adjusted EBITDA of $261.9 million, up 21.9%. The company also raised its full-year 2026 guidance, but it still reported a net loss attributable to NIQ of $30.5 million, larger than the $2.7 million loss in the same quarter of 2025.
Revenue of $1,124.2 million, up 8.0% year over year; organic constant currency growth of 5.8%
Net loss attributable to NIQ of $30.5 million versus $2.7 million a year earlier; adjusted EPS of $0.27 versus a $(0.01) loss
Adjusted EBITDA of $261.9 million, up 21.9%; adjusted EBITDA margin of 23.3%, up 270 basis points
Full-year 2026 guidance raised to 5.2% to 5.6% organic constant currency revenue growth, 23.5% to 23.9% adjusted EBITDA margin and $245 million to $255 million of levered free cash flow
Vera Therapeutics reported a second-quarter 2026 net loss of $109.5 million, or $1.52 per share, up from $76.5 million, or $1.20 per share, a year earlier. The company also said the FDA granted accelerated approval to TRUTAKNA for adults with primary IgA nephropathy at risk for disease progression, and that U.S. commercial launch is underway.
Q2 2026 net loss was $109.5 million ($1.52 per share), versus $76.5 million ($1.20 per share) in Q2 2025.
TRUTAKNA received FDA accelerated approval for adult primary IgAN patients at risk for disease progression.
Cash, cash equivalents and marketable securities were $499.2 million at June 30, 2026, plus up to $425 million available under a debt facility, subject to conditions.
Final ORIGIN 3 efficacy analysis is expected in Q3 2026, and the sBLA submission is expected in Q4 2026.
Kopin reported second quarter 2026 results for the period ended June 27, 2026, with total revenue up 51% to $12.7 million, driven mainly by grant, collaboration and research and development revenue. Net income attributable to common stockholders was $0.9 million, or $0.00 per share, compared with a net loss of $5.2 million, or $(0.03) per share, a year earlier, though the result was helped by a $2.1 million tax benefit and about $2.3 million of investment gains. The CFO said the company expects a solid second half of 2026 that exceeds its prior guidance.
Total revenue $12.7 million vs. $8.5 million in Q2 2025; product revenue $7.6 million vs. $7.5 million
Loss from operations $3.5 million vs. $5.5 million in Q2 2025
Net income $0.9 million ($0.00 per share) vs. net loss $5.2 million ($(0.03) per share), including a $2.1 million tax benefit
Management expects a solid second half of 2026 exceeding prior guidance and meaningful progress toward GAAP profitability in Q4 2026
Tactile Medical reported second-quarter 2026 revenue up 9% year-over-year to $85.7 million and net income of $7.8 million, or $0.34 per diluted share, compared with $3.2 million, or $0.14 per diluted share, a year earlier. The company lowered the top end of its full-year 2026 revenue forecast to $360 million to $366 million from $360 million to $368 million, citing temporary inventory dynamics tied to the AffloVest launch, while keeping its adjusted EBITDA outlook of $49 million to $51 million unchanged. Shareholders get profit growth alongside a narrower sales outlook.
Q2 2026 total revenue was $85.7 million, up from $78.9 million; airway clearance sales fell 7% on temporary inventory dynamics at a few large DME providers.
Q2 2026 net income was $7.8 million, or $0.34 per diluted share, versus $3.2 million, or $0.14 per diluted share, in Q2 2025.
Full-year 2026 revenue guidance is now $360 million to $366 million, versus the prior $360 million to $368 million.
Adjusted EBITDA guidance of $49 million to $51 million was maintained; cash was $69.9 million as of June 30, 2026.
P3 Health Partners reported second quarter 2026 total revenue of $386 million, up 9% from a year earlier, and net income of $15.7 million, compared with a net loss of $43.7 million in the prior-year quarter. The company raised its full-year 2026 adjusted EBITDA guidance to $80 million to $110 million, but the quarter includes favorable payer settlements and prior-year development, and at-risk membership fell 10% year over year.
Q2 2026 net income was $15.7 million, versus a net loss of $43.7 million in Q2 2025.
Q2 2026 adjusted EBITDA was $54.4 million, versus a loss of $17.1 million a year earlier.
Medical margin was $97.8 million for the quarter; excluding payer settlements and prior-year development, it was $52.9 million.
Full-year 2026 guidance: total revenue $1.5 billion to $1.6 billion; adjusted EBITDA $80 million to $110 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.